Bayer wins Schering AG

Share this article:
Germany’s Merck KGaA has agreed to sell its 21.8% stake in Schering AG, paving the way for rival Bayer to seize control of Schering AG. Bayer is expected to pay Merck KGaA $4.6 billion for its Schering AG stake upping the total purchase price for Schering AG to nearly $22 billion. The combined companies will form a German drug-manufacturing powerhouse to be  known as Bayer Schering Pharma. Schering AG’s product line includes several oncology drugs, including contraceptives Climara, Yasmin and Yaz -- and other specialty brands sold in the US by Schering AG affiliate Berlex.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.